| |
In this eBook discover more about the future of orphan drugs and the ways companies are enabling their drugs to get to market faster. Download today!
|
|
|
Wednesday, November 30, 2022 | 11am ET / 8am PT In this webinar, we will show how data centricity, digitalization and automation streamlines CMC content authoring and why it is the most viable solution to tackle the associated challenges. Register now.
|
|
| By Nick Paul Taylor Teva is taking another run at the FDA approval process. Months after the agency rejected the candidate, Teva has refiled for approval of its long-acting, subcutaneous schizophrenia treatment and talked up its prospects of launching the drug in the first half of next year. |
|
|
|
By Nick Paul Taylor Investors are betting that sublingual drug delivery can unlock the potential of a psychedelic, pumping $60 million into Lusaris Therapeutics to support clinical trials of a depression candidate. |
By Nick Paul Taylor A pair of phase 3 trials of Neurotech Pharmaceuticals’ encapsulated cell therapy implant have met their primary endpoints, positioning the biotech to talk to the FDA about bringing the treatment for a cause of central vision loss to market. |
By Nick Paul Taylor Fulgent Genetics is getting into the drug delivery game. Six years after splitting from its pharma arm, the company has reunited with its sibling in a $100 million deal that gives it control of a nano-drug delivery technology platform. |
|
Download this report for insights on the current market, trends & strategic partnerships driving innovation in orphan drugs. View the report.
|
|
By Zoey Becker After saying goodbye to biosimilars by divesting its copycat biologics franchise to Biocon Biologics, Viatris is saying hello to ophthalmology with the buyouts of Oyster Point Pharma and Fany Life Sciences. The two deals will add at least $1 billion in sales by 2028, the company said. |
Fierce podcastsDon't miss an episode |
| This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
|---|
|
|
|
Tuesday, November 29th, 2022 | 10am ET / 7am PT / 4pm CET Join our webinar to learn more on this fascinating topic where our experts will share their experiences and challenges in getting a repurposed drug to market successfully. The webinar will review case studies of successful drug repositioning to the nose to more intuitive and user friendly drug delivery. Register Now.
|
|
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| |
|
